5Schlesinger N. Overview of themanagement of acute gout and the role of adrenocorticotropic hormone. Drugs, 2008, 68(4): 407-415.
6Perez-Ruiz F, Mielgo F J, Beites AM. Optimisation of the treatment of acute gout. BioDrugs, 2000, 13(6): 415-423.
7Liot6F. Hyperuricemia and gout. Curr Rheumatol Rep,2003,5(3):227-234.
8Perez-Ruiz F, Atxotegi J, Hemando I, et al. Using serum urate levels to determine the period free of gouty symptonls after withdrawal of long-term urate-lowering therapy: a pro- spective study. ArthritisRheum, 2006, 55(5): 786-790.
9Kuo CF, Grainge M J, See LC, et al. Epidemiology and management of gout in Taiwan: a nationwide population study Arthritis Res Ther. 2015; 17: 13.
10Wallace KL, Riedel hA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004; 31 (8): 1582-1587.
